Few areas of psychiatry have reversed reputation as completely as psychedelic therapy. Substances once synonymous with the counterculture are now administered in university hospitals, in carefully screened sessions, to patients whose depression has resisted standard treatments. Trials of psilocybin — the active compound in magic mushrooms — report rapid, substantial improvements for some participants after one or two guided sessions. The results have attracted investment, media excitement and, in a few jurisdictions, legal medical services.
Enthusiasm needs the company of caution. Depression is a serious, sometimes life-threatening condition, and the World Health Organization estimates it affects hundreds of millions of people worldwide, many of whom are desperate for something that works. Our homepage coverage and Blog reporting examine what the trials actually show: real promise, specific risks, methodological puzzles and a regulatory path that remains unsettled.
What the Trials Have Found
The headline studies share a design: patients with major depression — often treatment-resistant, meaning at least two standard therapies have failed — receive one or two doses of psilocybin in a controlled setting, supported before, during and after by trained therapists. In several trials, depression scores fell sharply within days and remained lower for weeks or months in a substantial minority of participants. A notable trial comparing psilocybin with a standard antidepressant found broadly comparable outcomes, with some secondary measures favouring the psychedelic arm.
Researchers are careful about what this does and does not prove. Sample sizes remain modest, follow-up is shorter than the illness, and the comparison that matters most — against the best existing care, over years, in ordinary clinics — has barely begun. The signal is strong enough to justify large, expensive phase-three trials now underway; it is not yet strong enough to declare a new standard of care, and responsible researchers say so plainly.
The Blinding Problem and the Role of Therapy
Psychedelic trials face a methodological puzzle no statistical trick fully solves: participants know whether they received the drug. Expectations — primed by years of positive coverage — can inflate reported benefits, and disappointment in control groups can deflate theirs. Trialists fight back with active placebos that mimic some effects, independent raters who do not know group assignments, and pre-registered outcomes, but the field broadly accepts that its evidence carries an asterisk other drug classes do not.
Nor is the drug the whole intervention. The therapy around it — preparation, a six-to-eight-hour supported session, integration meetings afterwards — is intensive, expensive and possibly responsible for part of the benefit. That complicates regulation, which approves molecules more readily than experiences, and raises workforce questions: there are not thousands of therapists trained for this work, and shortcuts in training worry clinicians who have seen how vulnerable patients are in altered states.
Risks, Rules and What Comes Next
Safety data from screened trials look reassuring, but the screening is the point: people with psychosis risk, certain heart conditions and unstable circumstances are excluded, and sessions are medically supervised. Outside trials, unsupervised use carries real dangers, including terrifying experiences, risky behaviour and the triggering of latent illness. Regulators weighing approvals must therefore decide not just whether the therapy works, but what guardrails — licensing, supervision, registries — make its benefits available without abandoning its safeguards.
For patients, the honest position is narrow but hopeful. Psychedelic-assisted therapy is among the most interesting leads in a field short of breakthroughs, aimed initially at people current treatments have failed. It is not available as ordinary care in most places, not suitable for everyone, and not a reason to stop existing treatment. The trials now running will determine whether this decade’s most surprising psychiatric story becomes medicine — or a cautionary tale about hope outrunning evidence.
